Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Gastrointestinal Neoplasms 1

Interventions

Oxaliplatin 149Fluorouracil 136Gemcitabine 117Bevacizumab 115Leucovorin 106Specimen Handling 105Capecitabine 95pembrolizumab 89Magnetic Resonance Spectroscopy 83Cisplatin 79Nivolumab 77Irinotecan 71durvalumab 63Cetuximab 62Paclitaxel 60Biopsy 60130-nm albumin-bound paclitaxel 60atezolizumab 44Radiotherapy 44Taxes 36Carboplatin 36Albumin-Bound Paclitaxel 36Folfox protocol 35Drug Therapy 31Cyclophosphamide 30lenvatinib 29dehydroftorafur 28tislelizumab 27sintilimab 27Radiation 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Diltiazem × Gastrointestinal × 90 days × Clear all
NCT07456852 2026-06-02

Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy

Mayo Clinic

Phase 1/2 Recruiting
60 enrolled
Gastrointestinal

Gastrointestinal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡